HB 1200 amends Indiana’s opioid prescribing limits. Under the bill, a prescriber generally may issue an initial opioid prescription for no more than a seven-day supply when treating an adult for the first time, a child under 18, or an animal receiving an opioid for the first time from a veterinarian. The bill preserves existing exceptions for cancer treatment, palliative care, medication-assisted treatment for substance use disorder, and other conditions that the medical licensing board may exempt by rule. It also allows a prescriber to exceed the seven-day limit when, in the prescriber’s professional judgment, a longer course is medically necessary.
The bill adds documentation requirements when a prescriber relies on the palliative care or professional-judgment exceptions and determines that a non-opioid drug is not appropriate. For opioids administered through an intrathecal pump or epidural pain pump, the bill allows up to a 180-day supply and limits required face-to-face follow-up visits to once every 180 days unless earlier follow-up is medically necessary. The bill is effective July 1, 2025.
Impact
HB 1200 amends Indiana Code section 25-1-9.7-2, which governs opioid prescription limits, and expands the statute to explicitly address veterinary prescriptions and pump-administered opioids. It preserves the state’s general seven-day initial prescribing cap while clarifying exceptions and adding recordkeeping obligations for certain extended prescriptions. The bill affects prescribers, patients, veterinarians, and medical practices by setting default limits, documenting exceptions, and creating a longer treatment window for intrathecal and epidural pain pump therapy.
Sentiment
The voting record suggests broad bipartisan support and little opposition to the bill. It passed the House 87-0 and the Senate 49-0, indicating strong consensus around maintaining opioid prescribing limits while preserving medical exceptions for legitimate treatment needs. The absence of committee transcripts limits insight into debate, but the unanimous votes suggest the measure was viewed as a targeted, noncontroversial update to existing opioid policy.
Contention
There is little visible contention in the available record, but the main policy balance in the bill is between opioid misuse prevention and preserving prescriber discretion for patients with serious pain or special treatment needs. The most likely areas of concern are the scope of the professional-judgment exception, the documentation requirement for extended prescriptions, and the specific treatment of palliative care, cancer, medication-assisted treatment, and pump-based pain management. No recorded opposition appears in the vote totals, and no committee debate is available to show organized disagreement.